Research from Johns Hopkins University reveals psilocybin, the active compound in magic mushrooms, may be four times more effective than traditional antidepressants for severe depression. This small but promising trial aligns with prior studies.
Published in JAMA Psychiatry on November 4, 2020, the Johns Hopkins study examined psilocybin's effects on 24 patients with treatment-resistant depression persisting for over two years. Results showed rapid and significant symptom reduction. Notably, 71% of participants experienced at least a 50% drop in depression scores after four weeks, with 54% achieving remission after one month.
"The magnitude of these effects was about four times greater than what clinical trials have shown for traditional antidepressants," stated co-author Alan Davis.
While the study's small sample lacks a placebo control, it corroborates a decade of research supporting psilocybin for psychiatric conditions like anxiety and depression. A 2017 UK trial with 20 patients found it provided a breakthrough from depressive states. In August 2020, Canadian authorities approved psilocybin for four palliative care patients—the first legal use since its ban over 45 years ago.
Psilocybin is also under investigation for addiction. A 2015 Johns Hopkins study linked it to smoking cessation success, while University of British Columbia research that year showed similar benefits for alcohol dependence.
